Twelve-month results of a randomized trial comparing mono with dual antiplatelet therapy in endovascularly treated patients with peripheral artery disease

Journal of Endovascular Therapy

Volumn 20, Issue 5, 2013, Pages 699-706

  Strobl, Frederik F ^a,b   Brechtel, Klaus ^a   Schmehl, Jörg ^a   Zeller, Thomas ^c   Reiser, Maximilian F ^b   Claussen, Claus D ^a   Tepe, Gunnar ^a,d  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c Heart Centre   (Germany)

^d Department of Internal Medicine III   (Germany)

Author keywords

Antiplatelet therapy; Aspirin; Atherosclerosis; Balloon angioplasty; Clopidogrel; Mortality; Occlusion; Peripheral artery disease; Placebo controlled trial; Randomized controlled trial; Restenosis; Stenosis; Stent; Target lesion revascularization

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR STENT; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MALE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; ANGIOPLASTY, BALLOON; ASPIRIN; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GERMANY; HUMANS; MALE; MIDDLE AGED; PERIPHERAL ARTERIAL DISEASE; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; RECURRENCE; STENTS; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84885439855     PISSN: 15266028     EISSN: 15451550     Source Type: Journal    
DOI: 10.1583/13-4275MR.1     Document Type: Article

References (37)

1. Hunink MG, Wong JB, Donaldson MC, et al. Revascularization for femoropopliteal disease. A decision and cost-effectiveness analysis. JAMA. 1995;274:165-171.
2. Norgren L, Hiatt WR, Dormandy JA, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg. 2007;45 Suppl S:S5-67.
3. Goshima KR, Mills JL, Hughes JD. A new look at outcomes after infrainguinal bypass surgery: traditional reporting standards systematically underestimate the expenditure of effort required to attain limb salvage. J Vasc Surg. 2004;39:330-335.
4. Rocha-Singh KJ, Jaff MR, Crabtree TR, et al. Performance goals and endpoint assessments for clinical trials of femoropopliteal bare nitinol stents in patients with symptomatic peripheral arterial disease. Catheter Cardiovasc Interv. 2007;69:910-919.
5. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol. 2007;50:e1-e157.
6. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494-502.
7. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358:527-533.
8. Steinhubl SR, Berger PB, Mann JT, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288:2411-2420.
9. Harrington RA, Califf RM. Late ischemic events after clopidogrel cessation following drug-eluting stenting: should we be worried? J Am Coll Cardiol. 2006;48:2592-2595.
10. Sambu N, Warner T, Curzen N. Clopidogrel withdrawal: is there a "rebound" phenomenon? Thromb Haemost. 2011;105:211-220.
11. Eisenstein EL, Anstrom KJ, Kong DF, et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA. 2007;297:159-168.
12. Kandzari DE, Angiolillo DJ, Price MJ, et al. Identifying the "optimal" duration of dual antiplatelet therapy after drug-eluting stent revascularization. JACC Cardiovasc Interv. 2009;2:1279-1285.
13. Tepe G, Bantleon R, Brechtel K, et al. Management of peripheral arterial interventions with mono or dual antiplatelet therapy-the MIRROR study: a randomised and double-blinded clinical trial. Eur Radiol. 2012;22:1998-2006.
14. Dorffler-Melly J, Koopman MM, Prins MH, et al. Antiplatelet and anticoagulant drugs for prevention of restenosis/reocclusion following peripheral endovascular treatment. Cochrane Database Syst Rev. 2005(1):CD002071.
15. Ciuffetti G, Lombardini R, Pirro M, et al. Clopidogrel: hemorheological effects in subjects with subclinical atherosclerosis. Clin Hemorheol Microcirc. 2001;25:31-39.
16. Jagroop IA, Matsagas MI, Geroulakos G, et al. The effect of clopidogrel, aspirin and both antiplatelet drugs on platelet function in patients with peripheral arterial disease. Platelets. 2004;15:117-125.
17. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Clopidogrel withdrawal is associated with proinflammatory and prothrombotic effects in patients with diabetes and coronary artery disease. Diabetes. 2006;55:780-784.
18. Serebruany VL, Malinin AI, Bhatt DL. Paradoxical rebound platelet activation after painkillers cessation: missing risk for vascular events? Am J Med. 2006;119:707 e11-6.
19. Diehl P, Halscheid C, Olivier C, et al. Discontinuation of long term clopidogrel therapy induces platelet rebound hyperaggregability between 2 and 6 weeks post cessation. Clin Res Cardiol. 2011;100:765-771.
20. Ho PM, Fihn SD, Wang L, et al. Clopidogrel and long-term outcomes after stent implantation for acute coronary syndrome. Am Heart J. 2007;154:846-851.
21. Ho PM, Peterson ED, Wang L, et al. Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. JAMA. 2008;299:532-539.
22. Spertus JA, Kettelkamp R, Vance C, et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation. 2006;113:2803-2809.
23. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drugeluting stents. JAMA. 2005;293:2126-2130.
24. Brar SS, Kim J, Brar SK, et al. Long-term outcomes by clopidogrel duration and stent type in a diabetic population with de novo coronary artery lesions. J Am Coll Cardiol. 2008;51:2220-2227.
25. Ong AT, McFadden EP, Regar E, et al. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol. 2005;45:2088-2092.
26. Collet JP, Montalescot G, Steg PG, et al. Clinical outcomes according to permanent discontinuation of clopidogrel or placebo in the CHARISMA trial. Arch Cardiovasc Dis. 2009;102:485-496.
27. Sibbing D, Stegherr J, Braun S, et al. A doubleblind, randomized study on prevention and existence of a rebound phenomenon of platelets after cessation of clopidogrel treatment. J Am Coll Cardiol. 2010;55:558-565.
28. Van Werkum JW, Heestermans AA, Zomer AC, et al. Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry. J Am Coll Cardiol. 2009;53:1399-1409.
29. Berger PB. Optimal duration of clopidogrel use after implantation of drug-eluting stents-still in doubt. N Engl J Med. 2010;362:1441-1443.
30. Park DW, Yun SC, Lee SW, et al. Stent thrombosis, clinical events, and influence of prolonged clopidogrel use after placement of drug-eluting stent data from an observational cohort study of drug-eluting versus bare-metal stents. JACC Cardiovasc Interv. 2008;1:494-503.
31. Schulz S, Schuster T, Mehilli J, et al. Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period. Eur Heart J. 2009;30:2714-2721.
32. Stettler C, Wandel S, Allemann S, et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet. 2007;370:937-948.
33. Rossini R, Capodanno D, Lettieri C, et al. Prevalence, predictors, and long-term prognosis of premature discontinuation of oral antiplatelet therapy after drug eluting stent implantation. Am J Cardiol. 2011;107:186-194.
34. Kimura T, Morimoto T, Nakagawa Y, et al. Antiplatelet therapy and stent thrombosis after sirolimus-eluting stent implantation. Circulation. 2009;119:987-995.
35. Pfisterer M, Brunner-La Rocca HP, Buser PT, et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol. 2006;48:2584-2591.
36. Diehm C, Schuster A, Allenberg JR, et al. High prevalence of peripheral arterial disease and co-morbidity in 6880 primary care patients: cross-sectional study. Atherosclerosis. 2004;172:95-105.
37. Bhatt DL, Flather MD, Hacke W, et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol. 2007;49:1982-1988.